Although setmelanotide has been approved only for rare genetic forms of obesity, due to its role in reducing leptin resistance its potential effectiveness in non-genetic forms of obesity is still under investigation.61 In addition, as our understanding of the genetics of appetite-regulating pathways improves, further indications for setmelanotide treatment may emerge. Here, LEP is linked to obesity due to melanocortin 4 receptor deficiency.